The FDA on November 20, 2024, granted accelerated approval to ZIIHERA®, a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. ZIIHERA® is a product of Jazz Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
